Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in ...
To equip users with a complete next generation sequencing (NGS) solution from sample to answer, global genomics leader Integrated DNA Technologies (IDT),...
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patien...
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage spec...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Beghou announces the Beghou Arc Platform, a flexible, connected commercialization platform designed to help life sciences teams overcome data overload, r...
Sai Life Sciences (BSE: 544306 | NSE: SAILIFE), Agility Life Sciences, and Centrix Pharma Solutions today announced the launch of an Integrated CMC ...
The €190 million acquisition of VISUfarma marks a pivotal moment in Lupin’s transformation into a global specialty-led biopharma. With VISUfarma...
MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPhar...
BBG Advanced Therapies (BBGAT), a subsidiary of BioBridge Global (San Antonio, TX USA), and CELLforCURE, part of SEQENS Group (Les Ulis, France), are...
Industry report measures progress in six main areas: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government polic...
KARL STORZ, a global leader in minimally invasive surgical technology, is proud to announce it has received U.S. Food and Drug Administration (FDA) clear...
Avobis Bio LLC, a clinical-stage company developing implantable cell therapies, announced that the U.S. Food and Drug Administration ("FDA") has gr...
Leo Cancer Care announced that it has placed orders for TibaRay's advanced linear accelerators (linacs), which will be evaluated as an upgrade option to th...
© 2025 Biopharma Boardroom. All Rights Reserved.
